--- title: "Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Recommendation of \"Hold\" by Analysts" type: "News" locale: "en" url: "https://longbridge.com/en/news/233750693.md" description: "Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has received a consensus recommendation of \"Hold\" from fifteen research firms. Nine analysts rated it as hold, five as buy, and one as strong buy. The average twelve-month price target is $106.08. Recent ratings include a downgrade from Mizuho and an upgrade from Cantor Fitzgerald. The stock opened at $131.81, with a market cap of $14.04 billion. The company reported a quarterly EPS of ($0.16), missing estimates, and had revenue of $199.22 million, below expectations." datetime: "2025-03-30T06:52:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/233750693.md) - [en](https://longbridge.com/en/news/233750693.md) - [zh-HK](https://longbridge.com/zh-HK/news/233750693.md) --- # Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Recommendation of "Hold" by Analysts Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) has been assigned a consensus recommendation of "Hold" from the fifteen research firms that are currently covering the firm, MarketBeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $106.08. - MarketBeat Week in Review – 01/13 - 01/17 A number of research analysts have recently commented on the company. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, January 14th. StockNews.com initiated coverage on Intra-Cellular Therapies in a research report on Friday. They set a "hold" rating for the company. Mizuho downgraded shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and reduced their target price for the stock from $140.00 to $132.00 in a research report on Monday, February 24th. Baird R W cut shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Finally, Needham & Company LLC restated a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. **Get Our Latest Stock Analysis on ITCI** ## Intra-Cellular Therapies Stock Up 0.0 % - Is Johnson & Johnson Stock Set to Reward Long-Term Holders? NASDAQ:ITCI opened at $131.81 on Friday. The firm's fifty day simple moving average is $129.12 and its 200 day simple moving average is $99.63. Intra-Cellular Therapies has a twelve month low of $64.09 and a twelve month high of $131.87. The stock has a market cap of $14.04 billion, a P/E ratio of -151.50 and a beta of 0.69. Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, analysts expect that Intra-Cellular Therapies will post -0.64 EPS for the current fiscal year. ## Institutional Investors Weigh In On Intra-Cellular Therapies - Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals Several institutional investors have recently modified their holdings of ITCI. China Universal Asset Management Co. Ltd. lifted its stake in Intra-Cellular Therapies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock valued at $1,878,000 after acquiring an additional 2,157 shares during the period. Barclays PLC lifted its position in Intra-Cellular Therapies by 282.0% during the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock valued at $2,521,000 after purchasing an additional 25,435 shares during the period. Oak Ridge Investments LLC boosted its holdings in Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock worth $1,656,000 after purchasing an additional 8,440 shares during the last quarter. Principal Financial Group Inc. grew its position in Intra-Cellular Therapies by 3.3% in the 3rd quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company's stock worth $43,735,000 after purchasing an additional 18,865 shares during the period. Finally, Merit Financial Group LLC bought a new stake in Intra-Cellular Therapies in the 4th quarter worth approximately $206,000. 92.33% of the stock is owned by hedge funds and other institutional investors. ## About Intra-Cellular Therapies (Get Free Report Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. ## See Also - Five stocks we like better than Intra-Cellular Therapies - Insider Buying Explained: What Investors Need to Know - MarketBeat Week in Review – 03/24 - 03/28 - Following Congress Stock Trades - Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low - What Are the U.K. Market Holidays? How to Invest and Trade - 4 Healthcare Stocks With Massive Gains—and More to Come _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Intra-Cellular Therapies Right Now? Before you consider Intra-Cellular Therapies, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list. While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ITCI.US](https://longbridge.com/en/quote/ITCI.US.md) - [MFG.US](https://longbridge.com/en/quote/MFG.US.md) ## Related News & Research - [CX Institutional Has $7.37 Million Stock Holdings in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/294789236.md) - [Principal Financial Group Inc. Sells 6,022 Shares of Madrigal Pharmaceuticals, Inc. $MDGL](https://longbridge.com/en/news/294578126.md) - [UCB (ENXTBR:UCB) Stock Can Profit Momentum Calm Durability Doubts?](https://longbridge.com/en/news/294548283.md) - [Investors Buy Large Volume of Call Options on Astrazeneca (NYSE:AZN)](https://longbridge.com/en/news/294716282.md) - [An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it 'odd'](https://longbridge.com/en/news/294738560.md)